Liver disease is a significant risk factor for cardiovascular outcomes – A UK Biobank study
Adriana Roca‐Fernández(Hammersmith Hospital), Amitava Banerjee(University College London), Celeste McCracken(University of Oxford), Betty Raman(University of Leicester), Ntobeko Ntusi(John Radcliffe Hospital), Alison Telford, Thomas E. Nichols(University of Oxford), Rajarshi Banerjee(John Radcliffe Hospital), Arun J. Sanyal(Virginia Commonwealth University), Daniel J. Cuthbertson(University of Liverpool), Stefan Neubauer(John Radcliffe Hospital), Steffen E. Petersen(Queen Mary University of London), Helena Thomaides‐Brears, Michele Lai(Beth Israel Deaconess Medical Center), Andrea Dennis(Oxford Brookes University)
Cited by 109
Related Papers
The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases
|Hepatology|2017|7.2k
Tract-based spatial statistics: Voxelwise analysis of multi-subject diffusion data
|NeuroImage|2006|6.6k
Pioglitazone, Vitamin E, or Placebo for Nonalcoholic Steatohepatitis
|New England Journal of Medicine|2010|3.3k
A multisociety Delphi consensus statement on new fatty liver disease nomenclature
|Hepatology|2023|2.9k
A multisociety Delphi consensus statement on new fatty liver disease nomenclature
|Journal of Hepatology|2023|2.7k